drugset / Trial / NCT01418001
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Phase 1/2
Terminated
5 enrolled
Memorial Sloan Kettering Cancer Center
National Comprehensive Cancer Network · collabNorthwestern University · collabUniversity of California, Los Angeles · collabWashington University School of Medicine · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see the effects, good and/or bad, of the drug combination of gemcitabine, docetaxel and pazopanib on sarcoma. This is a phase Ib-phase II clinical trial. The goal of a phase Ib part of the clinical trial is to confirm a dose of the drugs that is safe. The investigators determine this by closely checking for side effects that the patient may experience.
Timeline
- Start
- 2011-08
- Primary completion
- 2015-11
- Completion
- 2015-11
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Pazopanib | Small molecule | 400 mg | — |